Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Gut Microbiome on Statin Response (INGEST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04098003
Recruitment Status : Recruiting
First Posted : September 20, 2019
Last Update Posted : November 1, 2019
Sponsor:
Information provided by (Responsible Party):
Sony Tuteja, University of Pennsylvania

Brief Summary:
There is evidence that the bacteria that naturally reside in the gut can influence how well we respond to medications. Therefore this study will look at how rosuvastatin, a medication used to lower cholesterol levels, may change the bacteria in the gut. Investigators will also examine how the gut bacteria will affect the ability of rosuvastatin to lower cholesterol levels. There will be 5 study visits over the course of about 16 weeks.The expected duration of the study is 2 years. Investigators plan to enroll 100 healthy volunteers during that time.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Rosuvastatin Drug: Placebo Phase 4

Detailed Description:

The gut microbiome plays an important role in the metabolism of xenobiotics and contributes to the variation in drug response. Atorvastatin, simvastatin and rosuvastatin, three of the most commonly prescribed statin medications, also display evidence for modulation by the gut microbiome.The objective of this study is to understand the interaction between the gut microbiome and host drug response to statin therapy using 16S rRNA sequencing, metagenomics sequencing and bile acid metabolomics.

Aim 1: To compare changes in the gut microbiome in healthy volunteers randomized to an 8-week intervention with rosuvastatin 10mg daily or placebo.

Aim 2: To determine the relationship with gut microbiome, fecal bile acid composition, serum FGF19 levels and the change in plasma LDL-C with rosuvastatin.

This is a randomized, placebo controlled trial to investigate the effects of rosuvastatin on the gut microbiome, fecal bile acids and FGF19 levels. Healthy volunteers will be randomized to rosuvastatin 20 mg daily or placebo for eight weeks in a 2:1 ratio. Participants will be blinded to treatment assignment. Stool and blood will be collected at baseline and 4, 8, and 12 weeks for 16S sequencing, plasma lipid assays, bile acid metabolites and FGF19 assays. A subgroup of participants at the tails of LDL-C response will undergo metagenomics sequencing.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomized, placebo controlled, double blind (participant and outcomes assessor) trial to investigate the effects of rosuvastatin on the gut microbiome. Healthy volunteers will be randomized to rosuvastatin 20 mg daily or placebo for eight weeks in a 2:1 ratio.
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Matching placebo capsules will be formulated
Primary Purpose: Basic Science
Official Title: INvestigation of the Gut microbiomE on STatin Response (INGEST)
Estimated Study Start Date : November 30, 2019
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rosuvastin
rosuvastatin 20 mg daily for eight weeks
Drug: Rosuvastatin
rosuvastatin 20 mg daily or placebo for eight weeks
Other Name: Crestor

Placebo Comparator: Placebo
placebo daily for eight weeks
Drug: Placebo
Matched placebo control




Primary Outcome Measures :
  1. Change in bacterial abundance [ Time Frame: 8 weeks ]
    as measured by operational taxonomic units (OTUs)


Secondary Outcome Measures :
  1. Change in LDL-C [ Time Frame: 8 weeks ]
    low density lipoprotein cholesterol levels (mg/dl)


Other Outcome Measures:
  1. Change in fecal bile acid concentrations [ Time Frame: 8 weeks ]
    concentration of bile acids (nM)

  2. Change in serum FGF19 levels [ Time Frame: 8 weeks ]
    Fibroblast growth factor 19 levels (pg/mL)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Participant is capable of giving informed consent
  2. Participant is aged 18 to 65 years. The gut microbiome has been shown to change gradually with time, although there is no cut-off in age when this occurs.

Exclusion Criteria:

  1. Participants with cardiovascular disease such as a history of heart failure (New York Heart Association class II-IV), myocardial infarction, stroke, coronary artery bypass graft, hypertension, and hyperlipidemia as these conditions are associated with altered gut microbiome composition.74 Hypertension is defined as blood pressure greater than 160/110 or on any anti-hypertensive medications. LDL-C >190 mg/dl or <100 mg/dl and triglycerides > 400 mg/dl.
  2. Participants with a history of cancer.
  3. Kidney disease (serum creatinine >1.5 mg/dl).
  4. Liver dysfunction (alanine aminotransferase > 2 times the upper limit of normal).
  5. Diabetes mellitus (DM) - Diabetes itself may affect the gut microbiome although this has not been extensively studied. In addition to a prior diagnosis of diabetes mellitus other than that related to pregnancy, a fasting glucose level of greater than 125mg/dL will be used to exclude participation.
  6. Clinical diagnosis of hypothyroidism
  7. History of inflammatory disorders of the intestinal tract (i.e. IBD, celiac sprue).
  8. Use of antibiotics in the prior 6 months.
  9. Use of pre-, pro-, or synbiotics.
  10. Chronic medication use (including over the counter medications and herbal supplements) with the exception of oral contraceptives. Since we are evaluating the impact of rosuvastatin on the gut microbiome we would like to exclude the potential impact of confounding medications.
  11. Current smoker. The effect of smoking on the microbiome of the gut is unknown.
  12. Known history of alcohol or substance abuse.
  13. Body Mass Index (BMI) <18.5 or >30 kg/m2. Volunteers with BMI below normal will be excluded to prevent inclusion of subjects with a subclinical systemic disease that may influence the gut microbiome. Volunteers with moderate or severe obesity will be excluded as obesity may be associated with altered gut microbiome composition.31
  14. Unable to abstain from consumption of illicit drugs during the study period.
  15. Prior bowel resection surgery other than appendectomy. It is unknown how prior bowel resection surgery may influence the microbiome composition; hence we will exclude these participants.
  16. Baseline bowel frequency less than every 2 days or greater than 3 times daily. Normal bowel frequency is every 3rd day to 3 times per day. Although unknown, stool frequency could be related to the microbiome composition. To avoid the need for use of antidiarrheal medications or laxatives, which themselves could alter the microbiome composition, these patients will be excluded.
  17. Participant has experienced diarrhea within the two weeks prior to entry. Diarrhea is defined as a change in bowel habits with an increased frequency or loose stools such that the stool could not be lifted with a fork.
  18. Vegans and Vegetarians.
  19. Known intolerance to statin medications.
  20. Unwilling to obtain from grapefruit containing foods or drinks.
  21. Pregnant women. To avoid any risk to an unborn fetus from study drug exposure.
  22. Refusal to use two medically accepted method of birth control while participating in the study, such as a barrier method, hormonal contraceptives, implanted birth control devices, permanent methods (such as a vasectomy), and/or abstinence.
  23. Nursing mothers
  24. Any condition that the investigator feels may limit the volunteer's ability to complete the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04098003


Contacts
Layout table for location contacts
Contact: Sony Tuteja, PharmD, MS 215-573-7834 sonyt@pennmedicine.upenn.edu
Contact: Karen Terembula, BS 215-615-3423 kterembu@pennmedicine.upenn.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Karen Terembula, BS    215-615-3423    kterembu@pennmedicine.upenn.edu   
Sponsors and Collaborators
Sony Tuteja
Investigators
Layout table for investigator information
Principal Investigator: Sony Tuteja, PharmD, MS University of Pennsylvania Perelman School of Medicine

Layout table for additonal information
Responsible Party: Sony Tuteja, Research Assistant Professor of Medicine, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT04098003     History of Changes
Other Study ID Numbers: 832874
First Posted: September 20, 2019    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Sony Tuteja, University of Pennsylvania:
gut microbiome
statins
cholesterol
Additional relevant MeSH terms:
Layout table for MeSH terms
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Enzyme Inhibitors